166 related articles for article (PubMed ID: 7146822)
1. Lymphopenia: a bad prognostic factor in Hodgkin's disease.
Hancock BW; Dunsmore IR; Swan HT
Scand J Haematol; 1982 Sep; 29(3):193-9. PubMed ID: 7146822
[TBL] [Abstract][Full Text] [Related]
2. The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms.
MacLennan KA; Hudson BV; Jelliffe AM; Haybittle JL; Hudson GV
Clin Oncol; 1981 Dec; 7(4):333-9. PubMed ID: 7318276
[No Abstract] [Full Text] [Related]
3. Immune status of untreated patients with Hodgkin's disease and prognosis.
Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
[TBL] [Abstract][Full Text] [Related]
4. Interrelationship between several prognostic factors in Hodgkin's disease.
Kotlarek-Haus S; Gabryś K; Starzyk H; Sciborski R; Gałazka Z
Arch Geschwulstforsch; 1982; 52(4):293-301. PubMed ID: 7138241
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
[TBL] [Abstract][Full Text] [Related]
7. SPLEEN/PATHOL.
Bukowski RM; Noguchi S; Hewlett JS; Deodhar S
Am J Clin Pathol; 1976 Jan; 65(1):30-9. PubMed ID: 1082240
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing features of the immunology of Hodgkin's disease in children.
Tan CT; De Sousa M; Good RA
Cancer Treat Rep; 1982 Apr; 66(4):969-75. PubMed ID: 7074657
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
Björkholm M; Holm G; Mellstedt H; Johansson B; Killander D; Sunblad R; Söderberg G
Scand J Haematol; 1978 Apr; 20(4):306-18. PubMed ID: 653310
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
Smith RS; Chen Q; Hudson MM; Link MP; Kun L; Weinstein H; Billett A; Marcus KJ; Tarbell NJ; Donaldson SS
J Clin Oncol; 2003 May; 21(10):2026-33. PubMed ID: 12743158
[TBL] [Abstract][Full Text] [Related]
13. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of immunocompetence in Hodgkin's disease.
Faguet GB
J Clin Invest; 1975 Oct; 56(4):951-7. PubMed ID: 1159096
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
18. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
Zhu YJ; Sun YL; Xia Y; Jiang WQ; Huang JJ; Huang HQ; Lin TY; Guan ZZ; Li ZM
Med Oncol; 2012 Jun; 29(2):1127-33. PubMed ID: 21390515
[TBL] [Abstract][Full Text] [Related]
20. [Immunological data in the clinical evaluation of Hodgkin's diseases].
Burchardt K
Z Gesamte Inn Med; 1981 Nov; 36(21):840. PubMed ID: 6977241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
